English
English
English
This discovery by the Tata Memorial Centre could provide a new direction to cancer treatment in India. Carboplatin not only provides affordable treatment, but also improves quality of life and long-term survival.
Tata Memorial Centre finds affordable breakthrough in breast cancer treatment
Mumbai: Tata Memorial Centre, the country's leading cancer treatment center, has achieved a major breakthrough in the treatment of breast cancer, particularly triple-negative breast cancer (TNBC), which is rapidly increasing in women. At a press conference on Friday, the institute announced that the low-cost chemotherapy drug carboplatin has proven highly effective in treating this disease.
Dr Sudip Gupta, Director of the Tata Memorial Centre, and Dr Rajendra A Badwe, former Director, stated at a press conference that the new study showed a significant improvement in the survival chances of breast cancer patients with carboplatin.
Dr Gupta said, "Overall, carboplatin increased the five-year survival rate by approximately 7.6 percent, which is statistically significant and clinically very beneficial."
The study was conducted on women of various age groups, particularly premenopausal women aged 50 years and younger, who benefited the most.
Health: These 6 foods must be included in your diet to prevent breast cancer
According to the institute's report, women who received carboplatin had a 77% chance of surviving five years, compared to 66% for those who did not receive the drug.
In addition, those who received carboplatin had a 12% higher chance of remaining cancer-free (from 62% to 74%).
However, no additional benefit was observed in women over 50 years of age. Experts believe that the drug is particularly effective in younger and premenopausal patients.
Importantly, no serious side effects were observed with carboplatin. The treatment was well tolerated by patients, and no additional toxicity was observed. Dr Gupta explained that "Giving carboplatin in weekly, lower doses facilitated patient completion of treatment and controlled side effects."
‘Dream of every young girl’: Breast Cancer survivor Miss World 2025 Opal Suchata
Dr Rajendra A Badwe, former Director of the Tata Memorial Centre, said, "The clarity of results from this single-institution trial conducted in India is inspiring. It proves that high-quality research conducted in India can benefit patients worldwide."
He further stated that this study will encourage doctors globally to incorporate carboplatin into the treatment of TNBC.
This discovery by the Tata Memorial Centre could provide a new direction to cancer treatment in India. Carboplatin not only provides affordable treatment, but also improves quality of life and long-term survival. This research brings new hope to women, that breast cancer treatment can now become more affordable, safe, and effective.
